MRV Research

Navigating the Changing Melanoma Landscape

Since 2011, four new medications have arrived on the scene for treating patients with melanoma. That’s good news for a potentially deadly cancer that had not seen a new drug approval in the preceding decade. Still, the glut of new treatment options does pose some significant management challenges.

Read More

Genentech’s Investigational Medicine Cobimetinib, Used in Combination with Zelboraf(R) (Vemurafenib), Helped People with Advanced Melanoma Live Significantly Longer Without Their Disease Worsening

Genentech, a member of the Roche Group today announced that the Phase III coBRIM study met its primary endpoint. The study demonstrated that the investigational MEK inhibitor cobimetinib, used in combination with Genentech’s BRAF inhibitor Zelboraf, helped patients with previously untreated BRAF V600 mutation-positive advanced melanoma live significantly longer without their disease worsening (progression-free survival; PFS) compared to Zelboraf alone. Adverse events were consistent with those observed in a previous study of the combination.

Read More
MRV News
Melanoma News
Archive
Menu